1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0284A
    Nifedipine hydrochloride
    Nifedipine hydrochloride is a potent vasodilator with calcium antagonist activity. Nifedipine hydrochloride is a useful antianginal compound that can also lower blood pressure. Nifedipine hydrochloride exhibits comparable antihypertensive properties to some new compounds, especially in calcium channel blockade. Nifedipine hydrochloride is used in biological activity studies to develop new antihypertensive and/or antianginal compounds.
    Nifedipine hydrochloride
  • HY-B2080
    Etidocaine
    Inhibitor
    Etidocaine (EDC) is a long aminoamide local anesthetic.
    Etidocaine
  • HY-161572
    Nav1.8-IN-13
    Inhibitor
    Nav1.8-IN-13 (compound 16) is a Nav1.8 inhibitor (pIC50=7.9).
    Nav1.8-IN-13
  • HY-P1681
    GpTx-1
    Antagonist
    GpTx-1 is a peptide-based NaV1.7 sodium channel antagonist isolated from the venom of the Chilean spider Grammostola porter. GpTx-1 demonstrates potent inhibitory activity against the NaV1.7 channel with an IC50 value of 10 nM, while exhibiting excellent selectivity for NaV1.4 (IC50 = 0.301 μM) and NaV1.5 (IC50 = 4.20 μM), showing >20-fold and >950-fold selectivity respectively.
    GpTx-1
  • HY-B0563BS
    Ropivacaine-d7 hydrochloride
    Inhibitor
    Ropivacaine-d7 hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B). Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is widely used for neuropathic pain management in vivo.
    Ropivacaine-d<sub>7</sub> hydrochloride
  • HY-100939
    4-Chlorophenylguanidine hydrochloride
    Agonist 99.07%
    4-Chlorophenylguanidine hydrochloride is an urokinase-type plasminogen activator inhibitor. 4-Chlorophenylguanidine hydrochloride is a potent ASIC3 positive allosteric modulator and reverses the effects of ASIC3 desensitization. 4-Chlorophenylguanidine hydrochloride influences ASIC3 activity through directly activating the channel and increasing proton sensitivity. 4-Chlorophenylguanidine hydrochloride offers a chemical backbone for the design of new ASIC3 ligands to study ASIC3 in vivo.
    4-Chlorophenylguanidine hydrochloride
  • HY-161085
    BI 1265162
    Inhibitor
    BI 1265162 is a potent inhibitor of endothelial sodium channel (ENaC) that plays an important role in cystic fibrosis research.
    BI 1265162
  • HY-126005
    VGSC blocker-1
    Inhibitor
    VGSC blocker-1 is a potent and small molecule blocker of neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5). VGSC blocker-1 blocks INa peak currents 34.9% at 1 μM and inhibits cell invasion 0.3% at 1 μM in human breast cancer cell line MDA-MB-231, without affecting the cell viability.
    VGSC blocker-1
  • HY-W031620
    VGSCs-IN-1
    Inhibitor
    VGSCs-IN-1 (compound 14), a 2-piperazine analog of Riluzole (HY-B0211), is a human voltage-gated sodium channels (VGSCs) inhibitor. VGSCs-IN-1 shows great Nav1.4 blocking activity. VGSCs-IN-1 has a pKa of 7.6 and a cLog P of 2.4. VGSCs-IN-1 can be used for cell excitability disorders research.
    VGSCs-IN-1
  • HY-P5800
    Phlo1b
    Inhibitor
    Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective Nav1.7 inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5.
    Phlo1b
  • HY-P5771
    Jingzhaotoxin-IX
    Inhibitor
    Jingzhaotoxin-IX, a C-terminally amidated peptide composed of 35 amino acid residues, is a neurotoxin. Jingzhaotoxin-IX inhibits voltage-gated sodium channels (both tetrodotoxin-resistant and tetrodotoxin-sensitive isoforms) and Kv2.1 channel. Jingzhaotoxin-IX has no effect on delayed rectifier potassium channel Kv1.1, 1.2 and 1.3.
    Jingzhaotoxin-IX
  • HY-B0516R
    Articaine hydrochloride (Standard)
    Inhibitor
    Articaine (Hoe-045) hydrochloride (Standard) is the analytical standard of Articaine hydrochloride (HY-B0516). This product is intended for research and analytical applications. Articaine (Hoe-045) hydrochloride is a selective inhibitor of voltage-gated sodium channels (such as rNav1.4, hNav1.7, and rNav1.8), with an IC50 of 15.8 μM for open-state Na+ channels, and IC50 of 40.6 μM and 378 μM for inactivated and resting-state Na+ channels, respectively. Articaine hydrochloride exerts local anesthetic activity by inhibiting Na+ influx to block nerve impulse conduction, and can also inhibit NF-κB activation and NLRP3 inflammasome pathways, exhibiting anti-inflammatory function. Articaine hydrochloride can be used in the study of dental local anesthesia and inflammatory-related diseases (such as acute kidney injury).
    Articaine hydrochloride (Standard)
  • HY-16952
    Bepridil
    Inhibitor
    Bepridil ((±)-Bepridil) is a calcium channel blocking agent used as antiarrhythmic agent. Bepridil inhibits both calcium and sodium currents, has research potential in certain ischemia-induced ventricular arrhythmias. Bepridil also has strong inhibition of SARS-CoV-2 from entry and replication inside Vero E6 and A549 cells.
    Bepridil
  • HY-P5868
    mHuwentoxin-IV
    Inhibitor
    mHuwentoxin-IV is a naturally modified Huwentoxin-IV (HY-P1220). mHuwentoxin-IV inhibits tetrodotoxin-sensitive (TTX-S) voltage-gated sodium channels of dorsal root ganglion neurons with an IC50 of 54.16 nM. mHuwentoxin-IV inhibition of tetrodotoxin-sensitive sodium channels is not reversed by strong depolarization voltages.
    mHuwentoxin-IV
  • HY-P1219
    Jingzhaotoxin-III
    Inhibitor
    Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC50 of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype.
    Jingzhaotoxin-III
  • HY-171738
    Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38
    Antagonist
    Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 can be used in cancer research.
    Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38
  • HY-P5783
    δ-Buthitoxin-Hj2a
    Agonist
    δ-Buthitoxin-Hj2a, a scorpion-venom peptide, is a potent NaV1.1 agonist with an EC50 of 32 nM. δ-Buthitoxin-Hj2a can be used for the Dravet syndrome (DS) research.
    δ-Buthitoxin-Hj2a
  • HY-156596A
    Aneratrigine hydrochloride
    Inhibitor
    Aneratrigine (hydrochloride) is a sodium channel protein type 9 subunit alpha blocker. Aneratrigine (hydrochloride) can be used for neuropathic pain diseases research.
    Aneratrigine hydrochloride
  • HY-123427
    Transcainide
    Inhibitor
    Transcainide (R 54718) is an orally active antiarrhythmic agent.
    Transcainide
  • HY-151360
    NHE3-IN-3
    Inhibitor
    NHE3-IN-3 (Compound 1) is a Na+/H+ exchanger isoform 3 (NHE3) inhibitor with pIC50 of 6.2 and 6.6 against human and rat NHE3, respectively. NHE3-IN-3 shows high (98%) oral bioavailability in Sprague–Dawley rats.
    NHE3-IN-3
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.